Access to European Union law
<a href="https://eur-lex.europa.eu/content/help/eurlex-content/experimental-features.html" target="_blank">More about the experimental features corner</a>
Choose the experimental features you want to try
EUR-Lex
Access to European Union law

This document is an excerpt from the EUR-Lex website

You are here
Use quotation marks to search for an "exact phrase". Append an asterisk (*) to a search term to find variations of it (transp*, 32019R*). Use a question mark (?) instead of a single character in your search term to find variations of it (ca?e finds case, cane, care).
Search tips
Need more search options? Use the Advanced search

Document 62019TA0696

    Case T-696/19: Judgment of the General Court of 8 July 2020 — Teva Pharmaceutical Industries v EUIPO (Moins de migraine pour vivre mieux) (EU trade mark — Application for EU word mark Moins de migraine pour vivre mieux — Absolute ground for refusal — No distinctive character — Article 7(1)(b) of Regulation (EU) 2017/1001)

    IO C 339, 12.10.2020, p. 19–19 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

    12.10.2020   

    EN

    Official Journal of the European Union

    C 339/19

    Judgment of the General Court of 8 July 2020 — Teva Pharmaceutical Industries v EUIPO (Moins de migraine pour vivre mieux)

    (Case T-696/19) (1)

    (EU trade mark - Application for EU word mark Moins de migraine pour vivre mieux - Absolute ground for refusal - No distinctive character - Article 7(1)(b) of Regulation (EU) 2017/1001)

    (2020/C 339/24)

    Language of the case: English

    Parties

    Applicant: Teva Pharmaceutical Industries Ltd (Petah Tikva, Israel) (represented by: J. Bogatz and Y. Stone, lawyers)

    Defendant: European Union Intellectual Property Office (represented by: L. Rampini and V. Ruzek, acting as Agents)

    Re:

    Action brought against the decision of the Fifth Board of Appeal of EUIPO of 12 August 2019 (Case R 778/2019-5), relating to an application for registration of the word sign Moins de migraine pour vivre mieux as an EU trade mark.

    Operative part of the judgment

    The Court:

    1.

    Dismisses the action;

    2.

    Orders Teva Pharmaceutical Industries Ltd to pay the costs.

    (1)  OJ C 413, 9.12.2019.

    Top